Abstract:ConspectusClustered, regularly interspaced, short palindromic repeat (CRISPR)/associated protein 9 (CRISPR/Cas9) is emerging as a powerful genome-editing tool, enabling precise and targeted modifications of virtually any genomic sequence in living cells. These technologies have potential therapeutic applications for cancers, metabolic diseases, and genetic disorders. However, several major challenges hinder the full realization of their potential. Specifically, CRISPR-Cas9 gene editors, whether delivered as plasmid DNA, mRNA/sgRNA, or ribonucleoprotein (RNP), exhibit poor membrane permeability, restricting their access to the intracellular genome, where the editing occurs. Additionally, these editors lack tissue or organ specificity, raising concerns about off-target editing at the tissue level that causes unwanted genotoxicity. Though a range of delivery carriers has been developed to deliver Cas9 editors, their effectiveness is often limited by a number of barriers at both the extracellular and intracellular levels. Moreover, the prolonged activity of Cas9 increases the risk of off-target editing at the genomic level. Therefore, it is crucial to develop efficient delivery vectors, along with molecular switches to safely regulate Cas9 activity.In this Account, we summarize our recent achievements in developing different types of materials that can efficiently deliver the plasmid DNA encoding Cas9 protein and single-guide RNA (sgRNA), or Cas9 RNP into cells to highlight the design considerations of carriers for safe and efficient delivery in vitro and in vivo. After elucidating the chemical and physical factors that are responsible for encapsulating and delivering these biomacromolecules, we further elucidate how we design the biodegradable polymeric carriers using dynamic disulfide chemistry, emphasize their safe and efficient delivery features for genome-editing biomacromolecules, and also introduce the integration of the intracellular delivery of genome-editing biomacromolecules with microneedle-based transdermal delivery to promote therapeutic genome editing for inflammatory skin disorders. Finally, we review how we exploit optical, chemical, and genetic switches to control the Cas9 activity in conjunction with targeted delivery to address the spatiotemporal specificity of gene editing in vivo and demonstrate their precision therapy against cancer and colitis treatment as proof-of-concept examples. In the final part, we will summarize the progress we have made and propose the future directions that may impact the field based on our own research outcomes.

Cascade dynamic assembly/disassembly of DNA nanoframework enabling the controlled delivery of CRISPR-Cas9 system

A Dual‐Enzyme–Responsive DNA‐Based Nanoframework Enables Controlled Co‐Delivery of CRISPR‐Cas9 and Antisense Oligodeoxynucleotide for Synergistic Gene Therapy

Self-assembled DNA Nanoclews for the Efficient Delivery of CRISPR-Cas9 for Genome Editing.

A Smart DNA Nanoassembly Containing Multivalent Aptamers Enables Controlled Delivery of CRISPR/Cas9 for Cancer Immunotherapy

Effective Genome Editing Using CRISPR-Cas9 Nanoflowers

pH‐Responsive Polymer Nanoparticles for Efficient Delivery of Cas9 Ribonucleoprotein With or Without Donor DNA

Supramolecular Nanosubstrate‐Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion

Nucleic acid nanostructure for delivery of CRISPR/Cas9‐based gene editing system

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

Endosomal Escape and Delivery of CRISPR/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework

Multistage Delivery Nanoparticle Facilitates Efficient CRISPR/dCas9 Activation and Tumor Growth Suppression in Vivo

A Proton‐Activatable DNA‐Based Nanosystem Enables Co‐Delivery of CRISPR/Cas9 and DNAzyme for Combined Gene Therapy

DNA Nanomaterials for Delivery of Clustered Regularly Interspaced Short Palindromic Repeats/Cas Systems

Quaternary ammonium-based nanosystem enables delivery of CRISPR/Cas9 for cancer therapy

A Non-Cationic Nucleic Acid Nanogel for the Delivery of the CRISPR/Cas9 Gene Editing Tool.

Polymeric micellar nanoparticles for effective CRISPR/Cas9 genome editing in cancer

Non-Viral CRISPR/Cas Gene Editing in Vitro and in Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 Mrna and Sgrna.

Convergent Arrangement of sgRNA and Cas9 in CRISPRsome for Transcellular Trafficking

Lipid, Inorganic, Polymer, and DNA Based Nanocarriers for Delivery of CRISPR/Cas9 System

Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing

Near-infrared Light Responsive Upconversion-Dna Nanocapsules for Remote-Controlled CRISPR-Cas9 Genome Editing